On June 5, 2023 Elicio, a developer of immunotherapies for the treatment of cancer, reported positive interim clinical data from the ongoing Phase 1 study of its lead asset, ELI-002, an investigational therapeutic cancer immunotherapy (Press release, Elicio Therapeutics, JUN 5, 2023, View Source [SID1234632555]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Elicio engineers proteins that appear frequently in cancerous cells but less frequently in healthy cells, and presents these to the immune system, together with an adjuvant (immune response booster) that brings the antigen directly to the lymph nodes, part of the body’s immune system.

In the past, immunotherapies for cancer have yielded fairly weak responses, but Elicio hopes that its immunotherapy will be more effective, thanks to the mechanism whereby the antigen is presented directly to the lymph nodes, and because its product tackles several proteins at once.

The company’s first product, ELI-002 2P, targets mutant KRAS-driven cancers. It says that the seven KRAS driver mutations targeted by the ELI-002 7P formulation are present in 25% of all solid tumors (that is, not blood cancers). The trial is designed to assess the safety, immunogenicity and antitumor activity of ELI-002 2P as a monotherapy in patients with mutant KRAS-driven tumors who are at high risk for relapse due to detection of MRD ( minimal residual disease) following standard surgery and chemotherapy.